Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals executive Samantha Pearce reported equity award activity in Jazz (JAZZ) shares. On January 16, 2026, she acquired 3,637 ordinary shares at a price of $0.0, delivered under performance share awards originally granted on March 3, 2023, after performance-based vesting requirements were certified as satisfied on that date.
Also on January 16, 2026, 1,599 ordinary shares were withheld at $171.16 per share to cover her tax obligations arising from the vesting and distribution of those performance share awards. After these transactions, she directly owned 42,993 ordinary shares of Jazz Pharmaceuticals. A footnote notes that she had previously acquired 140 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals executive Robert Iannone reported equity compensation activity involving the company’s ordinary shares. On January 16, 2026, he received 11,699 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were granted on March 3, 2023 after performance was certified. On the same date, 4,140 ordinary shares were withheld at $171.16 per share to cover his tax obligations related to the vesting and distribution of those awards.
Following these transactions, Iannone directly beneficially owned 80,258 ordinary shares of Jazz Pharmaceuticals. The filing also notes that he previously acquired 71 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported changes in her holdings of ordinary shares tied to performance-based equity awards. On January 16, 2026, she received 12,741 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were originally granted on March 3, 2023, after performance was certified as achieved.
On the same date, 5,371 ordinary shares were withheld at a price of $171.16 per share to cover her tax obligations related to the vesting and distribution of these performance share awards. Following these transactions, Gala directly beneficially owns 115,230 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported equity compensation and related tax withholding transactions in the company’s ordinary shares. On January 16, 2026, he received 35,917 ordinary shares at $0.0 per share, delivered under performance share awards that were originally granted on March 3, 2023 and certified as having met their performance-based vesting requirements on that date.
Also on January 16, 2026, 17,453 ordinary shares were disposed of at a price of $171.16 per share, with the filing explaining that these shares were withheld from the vesting and distribution of the performance share awards to satisfy his tax obligations. Following these transactions, Cozadd directly beneficially owned 411,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc reported that it plans to present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. In this presentation, the company states that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. Jazz also outlines expectations for revenue contributions in 2025 from key products Xywav, Epidiolex and Modeyso. The related presentation slides are provided as Exhibit 99.1.
Jazz Pharmaceuticals plc director Patrick Enright reported a transfer of 5,000 Ordinary Shares on 08/18/2025. The Form 4 shows this was a code J transaction, with a footnote explaining the shares were transferred to a former spouse without any payment as part of a comprehensive division of marital assets. After this transfer, Enright beneficially owned 21,379 Ordinary Shares, held directly.
Jazz Pharmaceuticals plc disclosed that senior vice president of technical operations Mary Elizabeth Henderson sold 2,238 ordinary shares on 12/09/2025. The transaction was reported with code "S" for an open-market or private sale at a weighted average price of $169.511, with individual trades executed between $169.00 and $169.82. Following these sales, she directly beneficially owns 19,508 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) director Heather McSharry reported an option exercise and share sale. On 11/20/2025 she exercised 3,415 non-qualified stock options at an exercise price of $138.08 per share, acquiring the same number of ordinary shares.
On the same date, she sold 3,415 ordinary shares at a price of $177.7823 per share. After these transactions, she directly beneficially owned 20,449 ordinary shares of Jazz Pharmaceuticals. The exercised options were originally granted in August 2016, fully vested by August 2017, and were scheduled to expire on 08/10/2026.
Jazz Pharmaceuticals senior vice president of technical operations Mary Elizabeth Henderson reported a sale of company stock in connection with equity compensation. On 11/19/2025, she disposed of 1,331 ordinary shares of Jazz Pharmaceuticals plc at a price of $180.4 per share, as shown in Table I of the filing. The filing states that these shares were sold to cover tax obligations from the vesting of previously granted restricted stock units, which is a common administrative transaction for equity awards. After this sale, she beneficially owned 21,746 ordinary shares, held directly.
Jazz Pharmaceuticals plc director reports share sales and RSU grant. A board member of Jazz Pharmaceuticals filed a Form 4 disclosing several open-market sales of ordinary shares on November 18, 2025 at weighted average prices ranging from $180.0859 to $182.6009. Following these transactions, the reporting person directly beneficially owned 390,826 ordinary shares.
On November 20, 2025, the director received 2,506 restricted stock units at a price of $0.0 under Jazz’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, increasing direct beneficial ownership to 393,332 ordinary shares. Each unit represents a contingent right to one ordinary share and, subject to continuous service and certain additional conditions, will vest in full on July 24, 2026.